StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
20
This month
1
This year
3
Publishing Date
2024 - 04 - 01
1
2024 - 03 - 25
1
2024 - 03 - 19
1
2023 - 10 - 24
1
2023 - 07 - 07
1
2022 - 12 - 07
2
2022 - 11 - 28
1
2022 - 10 - 03
2
2022 - 06 - 02
1
2022 - 05 - 31
2
2022 - 05 - 18
1
2021 - 09 - 16
1
2021 - 08 - 09
1
2020 - 12 - 31
2
2020 - 12 - 08
1
2020 - 12 - 02
1
Sector
Health technology
20
Tags
Acquisition
1
Active
1
Agreement
1
Alliances
1
Alzheimer
1
Alzheimer's
1
Alzheimer’s
4
America
2
Application
3
Auvelity
4
Axs-05
6
Axs-07
2
Business
3
Clinical-trials-phase-ii
2
Clinical-trials-phase-iii
3
Companies
5
Conference
13
Day
2
Deadline
9
Depression
6
Disease
4
Drug
4
Earnings
11
Europe
2
Events
4
Fda
5
Fda acceptance
2
Financial
14
Financial results
10
Global
4
Growth
2
Health
7
Major depressive disorder
11
Market
7
Meeting
7
Migraine
2
Money
2
N/a
72
Narcolepsy
6
New drug
3
Offering
4
Pharm-country
10
Pharmaceutical
2
Phase 2
2
Phase 3
5
Positive
6
Positive results
2
Publication
3
Report
12
Research
3
Results
32
Solriamfetol
11
Study
4
Sunosi
11
Therapeutics
79
Today
2
Treatment
12
Trial
20
Update
7
Year
5
Entities
4d molecular therapeutics inc
21
Abb ltd
72
Abbvie inc.
32
Achieve life sciences, inc.
21
Actinium pharmaceuticals, inc.
25
Aldeyra therapeutics, inc.
32
Alterity therapeutics limited
26
Altra industrial motion corp.
23
Alzamend neuro inc
20
Anavex life sciences corp.
21
Arcutis biotherapeutics, inc.
22
Arrival
21
Ascendis pharma a/s
20
Astellas pharma inc
22
Astrazeneca plc
52
Axsome therapeutics, inc.
20
Beigene, ltd.
23
Biovie inc.
23
Bioxcel therapeutics, inc.
25
Bristol-myers squibb company
48
Clearside biomedical, inc.
22
Cnh industrial n.v.
69
Cytokinetics, incorporated
24
Dynavax technologies corporation
23
Eli lilly and company
116
Enlivex therapeutics ltd.
24
Exelixis, inc.
28
Fortress biotech, inc.
29
Gates industrial corporation plc
25
Gilead sciences, inc.
23
Global industrial co
37
Honeywell international inc.
53
Horizon therapeutics public limited company
35
Hutchison china meditech limited
22
I-mab
21
Icon plc
26
Immix biopharma, inc.
23
Immunic, inc.
21
Immutep limited
25
Incyte corporation
28
Johnson & johnson
99
Johnson controls international plc
22
Merck & company, inc.
45
Moleculin biotech, inc.
30
Novartis ag
25
Novo nordisk a/s
32
Novocure limited
22
Ocugen, inc.
23
Orange
66
Pds biotechnology corporation
22
Pfizer, inc.
47
Plus therapeutics, inc.
29
Regeneron pharmaceuticals, inc.
30
Regenxbio inc.
27
Sanofi
165
Sellas life sciences group, inc.
23
Sorrento therapeutics, inc.
33
Stag industrial, inc.
32
Takeda pharmaceutical company limited
36
Thermo fisher scientific inc
28
Symbols
AXSM
20
Exchanges
Nasdaq
20
Crawled Date
2024 - 04 - 01
1
2024 - 03 - 25
1
2024 - 03 - 19
1
2023 - 10 - 24
1
2023 - 07 - 07
1
2022 - 12 - 07
2
2022 - 11 - 28
1
2022 - 10 - 03
2
2022 - 06 - 02
1
2022 - 05 - 31
2
2022 - 05 - 18
1
2021 - 09 - 16
1
2021 - 08 - 09
1
2020 - 12 - 31
2
2020 - 12 - 08
1
2020 - 12 - 02
1
Crawled Time
11:00
6
11:01
1
11:02
1
11:03
1
11:20
1
12:00
6
12:20
1
13:00
1
17:00
1
19:00
1
Source
www.biospace.com
7
www.globenewswire.com
13
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Trial
entities :
Axsome therapeutics, inc.
save search
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Published:
2024-04-01
(Crawled : 11:00)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
-17.38%
|
O:
0.32%
H:
0.0%
C:
-3.52%
treatment
trial
therapeutics
solriamfetol
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Published:
2024-03-25
(Crawled : 11:00)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
-18.52%
|
O:
3.64%
H:
0.35%
C:
-7.48%
axs-12
narcolepsy
symphony
trial
therapeutics
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Published:
2024-03-19
(Crawled : 11:00)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
-9.4%
|
O:
0.84%
H:
5.95%
C:
5.09%
treatment
trial
therapeutics
solriamfetol
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
Published:
2023-10-24
(Crawled : 11:00)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
5.98%
|
O:
1.98%
H:
2.15%
C:
0.76%
axs-05
conference
disease
alzheimer’s
trials
trial
therapeutics
results
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Published:
2023-07-07
(Crawled : 11:00)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
-11.08%
|
O:
0.69%
H:
0.07%
C:
-2.31%
treatment
trial
therapeutics
solriamfetol
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder
Published:
2022-12-07
(Crawled : 13:00)
- biospace.com/
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
-12.68%
|
O:
0.32%
H:
4.77%
C:
3.52%
auvelity
trial
therapeutics
major depressive disorder
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
Published:
2022-12-07
(Crawled : 12:20)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
-12.68%
|
O:
0.32%
H:
4.77%
C:
3.52%
auvelity
meeting
trial
therapeutics
major depressive disorder
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
Published:
2022-11-28
(Crawled : 12:00)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
15.66%
|
O:
25.02%
H:
12.17%
C:
5.22%
axs-05
disease
trial
therapeutics
alzheimer’s
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial
Published:
2022-10-03
(Crawled : 12:00)
- biospace.com/
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
47.29%
|
O:
2.08%
H:
1.19%
C:
-0.48%
sunosi
trial
therapeutics
solriamfetol
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
Published:
2022-10-03
(Crawled : 11:00)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
47.29%
|
O:
2.08%
H:
1.19%
C:
-0.48%
sunosi
trial
therapeutics
solriamfetol
Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder
Published:
2022-06-02
(Crawled : 19:00)
- biospace.com/
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
173.49%
|
O:
-2.12%
H:
0.0%
C:
0.0%
axs-05
trial
therapeutics
major depressive disorder
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical PsychiatryAXS-05
Published:
2022-05-31
(Crawled : 17:00)
- biospace.com/
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
172.25%
|
O:
10.36%
H:
0.0%
C:
0.0%
axs-05
trial
therapeutics
publication
phase 3
major depressive disorder
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
Published:
2022-05-31
(Crawled : 12:00)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
172.25%
|
O:
10.36%
H:
0.0%
C:
0.0%
axs-05
trial
therapeutics
publication
phase 3
major depressive disorder
Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry
Published:
2022-05-18
(Crawled : 12:00)
- biospace.com/
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
111.93%
|
O:
4.9%
H:
3.4%
C:
-4.3%
axs-05
trial
therapeutics
publication
phase 2
major depressive disorder
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
Published:
2021-09-16
(Crawled : 11:20)
- biospace.com/
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
137.09%
|
O:
-0.32%
H:
6.3%
C:
3.26%
narcolepsy
phase 3
trial
Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression
Published:
2021-08-09
(Crawled : 12:00)
- biospace.com/
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
29.52%
|
O:
-34.96%
H:
6.06%
C:
-17.06%
treatment
phase 2
depression
trial
Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
Published:
2020-12-31
(Crawled : 12:00)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
-21.07%
|
O:
1.25%
H:
0.51%
C:
-3.36%
disease
alzheimer
phase 3
trial
alzheimer’s
alzheimer's disease
alzheimer's
Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine
Published:
2020-12-31
(Crawled : 11:03)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
-21.07%
|
O:
1.25%
H:
0.51%
C:
-3.36%
positive
phase 3
results
trial
treatment
Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation
Published:
2020-12-08
(Crawled : 11:02)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
-18.81%
|
O:
4.18%
H:
0.33%
C:
-1.87%
positive results
positive
results
trial
depression
major depressive disorder
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
Published:
2020-12-02
(Crawled : 11:01)
- globenewswire.com
AXSM
|
$67.19
2.24%
200K
|
Health Technology
|
-8.02%
|
O:
0.66%
H:
3.28%
C:
2.84%
positive
results
depression
positive results
trial
treatment
Gainers vs Losers
79%
21%
Top 10 Gainers
AGBA
|
News
|
$1.22
205.0%
86M
|
Finance
EGOX
|
$0.0606
68.33%
250M
|
NVFY
|
$3.45
63.51%
20M
|
Consumer Durables
CHRO
|
$1.66
35.51%
70K
|
n/a
INDO
|
$5.43
33.09%
10M
|
Energy Minerals
ZCMD
|
$1.86
28.28%
29M
|
Commercial Services
PAPL
|
$2.07
26.22%
550K
|
RWOD
|
$10.08
26.05%
5.6M
|
n/a
AULT
|
$0.3022
24.82%
51M
|
Manufacturing
HUSA
4
|
$2.07
23.95%
2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.